PCRX · Healthcare
Pacira Biosciences Inc
19/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
26
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$959M
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Exchange
NasdaqGS
About PACIRA BIOSCIENCES INC
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to…
Who's behind the signal
Every informed buyer we can see on PCRX, across all three feeds.
Hedge funds · 5
Gotham Asset Mgmt (Greenblatt)
Increased +36%
AQR Capital Management
Increased +12%
D.E. Shaw & Co
Decreased −3%
Citadel Advisors
Decreased −3%
Millennium Management (Englander)
Decreased −54%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 2 on record
Disclosures from 2021-04-20 to 2021-05-06
The newest disclosure we hold for this stock is 2021-05-06.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2021-05-06 | Tom Malinowski · D-NJ | House | Bought | $1,001 - $15,000 |
| 2021-04-20 | Tom Malinowski · D-NJ | House | Bought | $1,001 - $15,000 |
Not a model pick — but on our radar.
PACIRA BIOSCIENCES INC isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
0
New positions
2
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+36%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+12%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−3%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−3%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−54%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to PACIRA BIOSCIENCES INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell PACIRA BIOSCIENCES INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订